Straits Times Index
3,260.29 -32.84 (-1.00%) Nikkei
37,889.97 -570.11 (-1.48%) Hang Seng
17,144.12 -57.15 (-0.33%) FTSE 100
8,040.38 -4.43 (-0.06%) Bitcoin USD
64,548.02 -2,216.61 (-3.32%) CMC Crypto 200
1,393.71 -30.39 (-2.13%)
CStone Pharmaceuticals (2616.HK)
| Previous close | 0.860 |
| Open | 0.880 |
| Bid | 0.880 x 0 |
| Ask | 0.920 x 0 |
| Day's range | 0.870 - 0.930 |
| 52-week range | 0.800 - 3.470 |
| Volume | |
| Avg. volume | 2,560,559 |
| Market cap | 1.173B |
| Beta (5Y monthly) | 0.16 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.310 |
| Earnings date | 27 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.55 |
PR NewswireCStone Pharmaceuticals Reports 2023 Annual Results and Business Updates
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today reported 2023 annual results and recent business updates.
PR NewswireCStone Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the National Medical Products Administration (NMPA) of China has approved the supplemental biologics license application (sBLA) for sugemalimab (Cejemly®) in combination with fluoropyrimidine- and platinum-containing chemotherapy as a first-line treatment for unresectabl
PR NewswireCStone sells to Servier its exclusive rights to TIBSOVO® in Greater China and Singapore
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, and Servier, a global independent pharmaceutical group, today announced an agreement whereby Servier acquires from CStone the exclusive rights to develop and commercialize TIBSOVO® (ivosidenib tablets) in Greater China and Singapore.
